Thirty four (34) of the total US FDA approved 103 therapeutic antibody drugs, accounts for
one third of the total approved mAbs, are formulated with high protein concentration (100 …

Large-molecule antibody biologics have revolutionized medicine owing to their superior
target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity …

3D bioprinting has recently emerged as a very useful tool in tissue engineering and
regenerative medicine. However, develo** suitable bioinks to fabricate specific tissue …

Although many subcutaneously (sc) delivered, high-concentration antibody formulations
(HCAF) have received regulatory approval and are widely used commercially, formulation …

Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …

Cartilage defects can result in pain, disability, and osteoarthritis. Hydrogels providing a
chondroregeneration‐permissive environment are often mechanically weak and display …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

Meat analogs produced by high moisture extrusion (HME) are considered to be one of the
products that have great potential for replacing real meat. The key issue as a meat analog is …

It has been nearly four decades since the first therapeutic monoclonal antibodies were
approved and made available for widespread human use. Herein, US and EU approved …

Therapeutic proteins with a high concentration and low viscosity are highly desirable for
subcutaneous and certain local injections. The shape of a protein is known to influence …